Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Tuesday reported third-quarter earnings of $3.19 billion. On a per-share basis, the Basel, Switzerland-based company said it ...

Novartis is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE OPERATING PROFIT: The Swiss pharmaceutical major is set to report $4.87 billion in core ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of ... and Crohn's disease in the US, ad highly-active RRMS in the EU. The looming competition piles further ...

Swiss pharmaceutical giant Novartis raised its 2024 financial targets Tuesday after posting rising sales and margins in the third quarter, thanks in part to increased production of a prostate ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...